HRTX · Heron Therapeutics, Inc. /De/

$0.48 +0.01 (+2.13%) At close · Jul 20

Market Cap

$90.93M

189.28M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark Hensley	COO	$372,212	—	$1,210,000	$2,527,680	$187,108	$10,500	$4,307,500
Craig Collard	CEO	$689,431	—	$946,254	$1,352,917	$517,189	$10,500	$3,516,291
William Forbes	Chief Development Officer	$609,881	—	$318,087	$454,788	$305,009	—	$1,687,765
Ira Duarte	CFO	$559,803	—	$318,087	$454,788	$287,500	$10,500	$1,630,678

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Ira Duarte	CFO	$592,250	—	$129,557	$473,779	$340,544	—	$1,536,130
William Forbes	Chief Development Officer	$592,250	—	$129,557	$473,779	$340,544	—	$1,536,130
Craig Collard	CEO	$515,000	—	$129,557	$473,779	$296,125	$10,350	$1,424,811
Mark Hensley	COO	—	—	—	—	—	—	—

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Craig Collard	CEO	$492,986	—	$547,273	$9,257,049	$326,957	$151,553	$10,775,818
Ira Duarte	CFO	$271,154	—	$60,500	$1,066,875	$128,844	$7,500	$1,534,873
William Forbes	Chief Development Officer	$329,519	—	$55,500	$917,433	$155,654	—	$1,458,106
Mark Hensley	COO	—	—	—	—	—	—	—

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kimberly Manhard	Senior Vice President of Global Strategic Planning and Execution	$545,834	—	$441,456	$235,482	$204,688	$19,647	$1,447,107
David Szekeres	COO	$533,013	—	$441,456	$235,482	$199,880	$19,400	$1,429,231
Barry Quart	CEO	$736,000	—	—	—	$386,400	$23,304	$1,145,704
Ira Duarte	CFO	—	—	—	—	—	—	—
William Forbes	Chief Development Officer	—	—	—	—	—	—	—
Craig Collard	CEO	—	—	—	—	—	—	—

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Barry Quart	CEO	$700,000	—	$2,061,649	$2,268,479	$392,000	$8,700	$5,430,828
Kimberly Manhard	Senior Vice President of Global Strategic Planning and Execution	$514,937	—	$583,626	$535,147	$205,975	$18,893	$1,858,578
John Poyhonen	President and CCO	$509,748	—	$583,626	$535,147	$203,899	$8,700	$1,841,120
David Szekeres	COO	$494,400	—	$583,626	$535,147	$197,760	$18,498	$1,829,431
Lisa Peraza	Chief Accounting Officer	$339,900	—	$247,123	$75,530	$118,965	$15,237	$796,755

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Barry Quart	CEO	$676,838	—	$916,995	$3,366,895	$364,991	$21,084	$5,346,803
John Poyhonen	President and CCO	$513,935	—	$314,400	$1,635,349	$197,960	$8,550	$2,670,194
David Szekeres	COO	$476,910	—	$314,400	$1,500,673	$161,664	$8,550	$2,462,197
Kimberly Manhard	Senior Vice President of Global Strategic Planning and Execution	$519,167	—	$314,400	$1,154,364	$199,976	$8,550	$2,196,457
Lisa Peraza	Chief Accounting Officer	$328,805	—	$138,855	$990,829	$105,683	$14,567	$1,578,739
Robert Hoffman	CFO	$360,009	—	—	—	—	$668,287	$1,028,296

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Barry Quart	CEO	$638,991	—	—	$4,916,373	$306,715	$8,400	$5,870,479
John Poyhonen	President and CCO	$216,731	—	—	$4,211,063	$90,751	$6,219	$4,524,764
Kimberly Manhard	Senior Vice President of Global Strategic Planning and Execution	$490,136	—	—	$1,815,276	$196,054	$8,400	$2,509,866
Drug Development	—	$490,136	—	—	$1,815,276	$196,054	$8,400	$2,509,866
Robert Hoffman	CFO	$388,714	—	—	$1,512,730	$124,388	$8,400	$2,034,232
Robert Rosen	Director	$78,645	—	—	—	—	$1,022,386	$1,101,031

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Barry Quart	CEO	$614,414	—	—	$4,815,660	$552,973	$8,250	$5,991,297
Robert Rosen	Director	$614,414	—	—	$4,815,660	$552,973	—	$5,983,047
Kimberly Manhard	Senior Vice President of Global Strategic Planning and Execution	$466,796	—	—	$1,605,220	$350,097	$8,250	$2,430,363
Drug Development	—	$466,796	—	—	$1,605,220	$350,097	$8,250	$2,430,363
Robert Hoffman	CFO	$357,438	—	—	$1,139,706	$214,463	$8,027	$1,719,634
John Poyhonen	President and CCO	—	—	—	—	—	—	—

Fiscal 2017

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Barry Quart	CEO	$596,518	—	—	$3,391,524	$246,958	$8,100	$4,243,100
Robert Rosen	Director	$596,518	—	—	$3,391,524	$246,958	—	$4,235,000
Robert Hoffman	CFO	$235,577	—	—	$1,972,207	$68,425	$3,635	$2,279,844
Drug Development	—	$453,200	—	—	$1,312,848	$156,354	$8,100	$1,930,502
John Poyhonen	President and CCO	—	—	—	—	—	—	—

Key facts CIK 818033 CUSIP 427746102 13F (30d) 14 filings 14 filers Visit website Investor relations